Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 c...

Full description

Saved in:
Bibliographic Details
Main Authors: Tanguy Dequidt, Quentin Richier, Céline Louapre, Florence Ader, Yanis Merad, Nicolas Lauwerier, Christine Jacomet, Michel Carles, Charlotte Biron, Vincent Gendrin, Clément Marlat, François Danion, Tristan M Lepage, Albert Sotto, Loïc Bourdellon, Alexandre Mania, Martin Martinot, Georges Le Falher, Alexis Ferre, Benoit Pilmis, Guillaume Gondran, Pierre Simeone, Matthieu Henry, Toufik Kamel, Simon Ray, Sophie Ancellin, Nicolas Mélé, Fabrice Camou, Marjolaine Destremau, Jeremy Sellenet, Noémie Zucman, Marion Le Maréchal, Khawla Mellouki, Marie-Elodie Langlois, David Luque Paz, Maud Mousset, Catherine Leclerc, Agnès Sommet, Karine Lacombe, Guillaume Martin-Blondel
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
Protracted COVID-19
Convalescent plasma
Anti-CD20 antibodies
Multiple sclerosis
Neuromyelitis optica
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971224003989
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2. Methods: This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration. Results: Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP. Conclusions: CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.
ISSN:1201-9712

Similar Items